login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TG THERAPEUTICS INC (TGTX) Stock News
USA
- NASDAQ:TGTX -
US88322Q1085
-
Common Stock
34.55
USD
+0.86 (+2.55%)
Last: 10/28/2025, 8:24:22 PM
34.5
USD
-0.05 (-0.14%)
After Hours:
10/28/2025, 8:24:22 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TGTX Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: TG Therapeutics, Inc.
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
13 days ago - By: Benzinga
- Mentions:
AMGN
BIIB
NVS
CLYM
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
a month ago - By: Benzinga
- Mentions:
VRTX
DHR
HUM
MDT
...
10 Health Care Stocks Whale Activity In Today's Session
a month ago - By: TG Therapeutics, Inc.
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
2 months ago - By: Stocktwits
TG Therapeutics Board Authorizes New $100M Share Repurchase Program
3 months ago - By: Zacks Investment Research
- Mentions:
TSN
W
ON
Company News for Aug 5, 2025
2 months ago - By: TG Therapeutics, Inc.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2 months ago - By: TG Therapeutics, Inc.
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
2 months ago - By: TG Therapeutics, Inc.
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Yahoo Finance
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback
3 months ago - By: Investor's Business Daily
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook
2 months ago - By: Zacks Investment Research
- Mentions:
INCY
Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?
2 months ago - By: TG Therapeutics, Inc.
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
2 months ago - By: TG Therapeutics, Inc.
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
3 months ago - By: Yahoo Finance
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance
3 months ago - By: Zacks Investment Research
- Mentions:
CRMD
ARVN
IMCR
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
3 months ago - By: Stocktwits
- Mentions:
IWMW
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
3 months ago - By: Yahoo Finance
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
3 months ago - By: The Motley Fool
TG Therapeutics Q2 Revenue Up 91%
3 months ago - By: TG Therapeutics, Inc.
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
3 months ago - By: TG Therapeutics, Inc.
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
CSTL
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
4 months ago - By: Yahoo Finance
Jim Cramer on TG Therapeutics: “You Should Buy the Stock”
Please enable JavaScript to continue using this application.